Beijing Mesochem Technology Co., Ltd.

More
Business Type:Manufacturer/Factory & Trading Company
R&D Capacity:Own Brand, OEM, ODM
Main Products:Adapalene, Lorcaserin Hydrochloride, Tofacitinib Citrate, Avanafil, Baricitinib, Osimertinib, Regorafenib Hydrate, Netupitant, Clascoterone, Molnupiravir, PF-07321332, Crizotinib, Relugolix, Trifarotene, Olaparib
Year of Establishment:2009-11-13
{"app": "App", "root": "#root", "props": "#ssrData", "options": {"type":"react","main":false,"router":"none","base":"","path":"","csr":false}}
Info marked by "" is verified by SGS. Click here to view the full report.

Company Overview

Beijing Mesochem Technology Co., Ltd. Is founded in 2009 as an independent high-tech enterprises specializing in Pharmaceutical chemicals and fine chemicals, it aims to to adapt to the business development of Beijing Huafeng United Technology Co., Ltd established in 2005.

The company locates in "Pharm Valley" Beijing Economic and Technological Development Zone(BDA), devotes to active pharmaceutical ingredient, intermediates and Pharmaceutical technology development services. It has independent R&D ability and right of import-export operations and has already established stable cooperation relationship with hundreds of pharmaceutical companies and research institutions both at home and abroad.

Beijing Mesochem Technology Co., Ltd has two production base at Xingan (Jiangxi Province) and Xiangyang (Hubei province), with production area about 67000 m2 and various of manufacturing equipment amount to 30000L, it has the ability of R&D, pilot production and commercial production. 80% of the products are exported to Europe, North America, South America, India and Pakistan, Southeast Asia and so on.

We started to construct a cGMP formulation plant in 2014 which was put into use in the end of 2016. The plant has 4 units including oral solid formulation &injection workshop, anesthetics workshop, warehouse and QC lab. The annual capacity of oral dosages is 2billion tablets, and for injection is 9million ampoules, and the filling capacity for inhaled anesthetics is 12million bottles per year. Two ANDAs are under review of FDA. And more than ten formulations have applied for marketing authorization in many regulatory markets.

All the internal quality control criteria are more stringent than the National regulatory criteria, quality assurance system is established to meet the requirements of FDA, ICH, EDQM, etc.

Member Info

Manufacturer/Factory & Trading Company
Adapalene, Lorcaserin Hydrochloride, Tofacitinib Citrate, Avanafil, Baricitinib, ...
2009-11-13
35
Floor 23, Building 9, Lippo Plaza, Ecouomic and Techenological Decelopment Zone, Beijin, Beijing, China
false

General Information

Manufacturer/Factory & Trading Company
Adapalene, Lorcaserin Hydrochloride, Tofacitinib Citrate, Avanafil, Baricitinib, ...
2009-11-13
35
Floor 23, Building 9, Lippo Plaza, Ecouomic and Techenological Decelopment Zone, Beijin, Beijing, China
800 square meters
1,000,000 RMB

Trade Capacity

North America, South America, Europe, Southeast Asia/ Mideast, Africa, East Asia(Japan/ South Korea), Australia, Domestic
7
FOB, CIF, CFR
LC, T/T, D/P, PayPal, Western Union
Peak Season Lead Time: one month
Off Season Lead Time: one month
No
2010-04-01
Tianjin Port

R&D Capacity

Yes
Yes
Yes
3 people
Processing Facility